Processa Pharmaceuticals, Inc.
PCSA· Nasdaq
PCSAProcessa Pharmaceuticals, Inc.
Filed Sep 25, 2017 · 10-K · 268 days after period end · 0001393905-17-000290
| Metric | Q4 2016 | Q4 2015dderived from reported figures | Q4 2014dderived from reported figures | Q4 2013dderived from reported figures |
|---|---|---|---|---|
| Revenue | $0.00 | — | — | $70.09K |
| Net Income | -$234.34K | -$362.77K | -$1.54M | -$806.93K |
| EPS Diluted | -$0.01 | — |
Processa Pharmaceuticals, Inc. · CIK 1533743 · Engraved from SEC EDGAR
| — |
| — |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
ended Dec 31, 2016 · filed Sep 25, 2017 · 268 d after period end
